Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
Better Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
10/06/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
08/25/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
08/14/2023 SC 13D/A David P. Perry 2015 Trust reports a 32.5% stake in Better Therapeutics, Inc.
08/11/2023 D Form D - Notice of Exempt Offering of Securities:
08/09/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Better Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates Obtained FDA Authorization for AspyreRxTM to treat adults with type 2 diabetes Established price and launch metrics in preparation for expected launch in Q4 Completed financing transactions totaling $12.5 million in net proceeds Company to host conference call and webcast today at 4:30pm ET"
07/31/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/26/2023 8-K Quarterly results
07/26/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Better Therapeutics Receives FDA Authorization for AspyreRxTM to Treat Adults with Type 2 Diabetes First prescription digital behavioral therapeutic device delivering novel form of cognitive behavioral therapy via smartphone In a randomized controlled trial AspyreRx demonstrated clinically meaningful and statistically significant durable reductions in A1c Company to host conference call and webcast on July 11 at 8:30 a.m. ET"
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Opinion of Goodwin Procter LLP",
"ATM Sales Agreement, by and between Better Therapeutics, Inc., and Virtu Americas LLC"
05/11/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Better Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates On track for an FDA decision mid-year Announced restructuring to extend cash runway Completed private placement financing Company to host conference call and webcast today at 8:30 a.m. ET"
04/26/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/26/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/25/2023 ARS Form ARS - Annual Report to Security Holders:
04/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/24/2023 8-K Quarterly results
04/21/2023 D Form D - Notice of Exempt Offering of Securities:
04/20/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
04/14/2023 8-K Quarterly results
04/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
03/30/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/30/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/30/2023 10-K Annual Report for the period ended December 31, 2022
03/30/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
02/07/2023 SC 13G/A Farallon Capital Partners, L.P. reports a 3.4% stake in Better Therapeutics, Inc.
12/07/2022 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy